Laddar...
Review of cardiovascular outcomes trials of sodium – glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists
PURPOSE OF REVIEW: In recent years, there have been several cardiovascular outcomes trials (CVOT) of two new classes of glucose-lowering medications: sodium–glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA). It is important examine their potential...
Sparad:
| I publikationen: | Curr Opin Cardiol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6876849/ https://ncbi.nlm.nih.gov/pubmed/31436559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HCO.0000000000000673 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|